Alkyl Amines Chemicals Ltd Q3 FY26 – ₹354 Cr Revenue, ₹42 Cr PAT, 18–19% OPM… but why is the stock still sulking?
1. At a Glance – Blink and You’ll Miss the Drama
Alkyl Amines Chemicals Ltd is that classic Indian specialty chemicals stock that once made investors feel like geniuses and is now making them feel like long-term yoga practitioners—patient, flexible, and slightly sore. With a market cap of ~₹8,258 Cr, the stock trades at ₹1,616, down ~23% in six months and ~15% over three years, while still flaunting a P/E of ~45.7x like it’s 2021 and liquidity is free.
Q3 FY26 numbers? Respectable, not fireworks. Revenue ₹354 Cr (–4.6% QoQ), PAT ₹42.3 Cr (–3.4% QoQ), margins steady at ~19% OPM, debt basically zero, ROCE ~18.7%, ROE ~14%. This is not a sick company—this is a bored company in a bored phase.
Volumes are stable, margins are holding, management is talking about 10–15% volume growth in FY26, and yet the stock behaves like it just failed a chemistry practical. So what’s going on? Is this a temporary chemistry lab pause, or has Alkyl Amines entered its “mid-life crisis” phase? Let’s open the lab notebook.
2. Introduction – From Darling to Detention Bench
Alkyl Amines was once the poster child of Indian specialty chemicals. Global leadership in aliphatic amines, niche products, clean balance sheet, export muscle—textbook compounder vibes. Then came peak margins during FY21–FY22, global supply disruptions, China exits, and suddenly Alkyl looked invincible.
Fast forward to FY24–FY26, and reality has returned with a lab coat. Demand softened, pharma and agro slowed, exports normalized, and growth numbers stopped doing backflips. The company is still profitable, still disciplined, still conservative—but markets don’t clap for “still”. They clap for “surprise”.
This is not a company collapsing. This is a company digesting. The real question is: is Alkyl Amines digesting before the next sprint, or before retirement?
3. Business Model – WTF Do They Even Do?
In simple terms, Alkyl Amines plays with ammonia and turns it into money.
They manufacture aliphatic amines and derivatives, which are core building blocks for pharma APIs, agrochemicals, dyes, rubber chemicals, water treatment chemicals, surfactants, polymers, paints, coatings, and half the periodic table’s social circle.
They sell 100+ products, many of which are globally niche. Some products are so niche that Alkyl Amines is the only global producer. That’s not monopoly—that’s chemical loneliness.
Revenue mix FY25:
Amines & derivatives – 79%
Specialty chemicals – 21%
Over time, Alkyl wants specialty chemicals to grow faster because:
Better margins
Stickier customers
Less China-style price wars
But specialty chemicals don’t scale overnight. They scale like Indian rail projects—slow approvals, long gestation, then sudden visibility.
4. Financials Overview – The Numbers Don’t Lie, They Just Yawn
Average EPS = ₹8.78 Annualised EPS ≈ ₹35.1 (matches TTM ₹35.3, so no jugaad here)
Performance Table (₹ Cr)
Metric
Latest Qtr (Q3 FY26)
YoY Qtr (Q3 FY25)
Prev Qtr (Q2 FY26)
YoY %
QoQ %
Revenue
354
371
389
–4.6%
–9.0%
EBITDA
67
71
70
–5.6%
–4.3%
PAT
42.3
44
43
–3.9%
–3.4%
EPS (₹)
8.26
8.56
8.40
–3.5%
–1.7%
Commentary: No collapse. No explosion. Just… meh. Margins are holding, volumes are not exploding, and customers are clearly not panic-buying chemicals anymore.
Question for you: Would you pay 45x earnings for “meh”?
5. Valuation Discussion – Paying for Potential, Not Performance
Method 1: P/E Multiple
Annualised EPS: ~₹35
Conservative multiple: 25–30x
Implied value range: ₹875 – ₹1,050
Method 2: EV/EBITDA
EBITDA TTM ~₹282 Cr
Reasonable EV/EBITDA: 15–18x
EV range: ₹4,200 – ₹5,100 Cr
Equity value range (low debt): ₹800 – ₹1,000
Method 3: DCF (High-level sanity check)
Growth assumption: 8–10%
Margin stability: ~18–19%
Conservative discount rate
Result: low four-digit fair value
Fair Value Range (Educational): ₹850 – ₹1,050
This fair value range is for educational purposes only and is not investment advice.
So yes, at ₹1,616, the market is clearly pricing in future growth acceleration, not current numbers.
6. What’s Cooking – News, Triggers, Drama
Anti-dumping duty on Acetonitrile recommended (China-focused), approval pending. If approved, margins smile again. If delayed, business continues like a Monday morning.
New specialty chemical plant at Dahej (3,000–4,000 MTPA, ₹115–150 Cr capex). Timeline: 15–50 months. Translation: don’t hold your breath.
Clarification on volume spike in Jan 2026—company says nothing undisclosed. Market was probably just bored.
